TB Testing within Public Health
The WHO’s End TB Strategy and the CDC Guidelines recommend testing high risk populations for LTBI, and treating LTBI to prevent progression to active TB. 1,2
TB Elimination Requires Diagnostics, Treatment and Funding
Advanced tests, such as the T-SPOT.TB test, help identify patients with tuberculosis. The T-SPOT.TB test is a single-draw, single-visit TB test that offers fast, reliable results even for BCG vaccinated or immunocompromised patients. It is the only IGRA that separates cells from whole blood and standardizes the number of cells used in each patient test, reducing the risk of false negative and invalid test results. Additionally, the T-SPOT.TB test is the only TB test with both sensitivity and specificity exceeding 95%.3
Public health leaders have chosen to switch to the T-SPOT.TB test when screening:
- Persons exposed to active TB (contact investigations)
- HIV patients
New LTBI treatments, such as 3HP, short course therapy, may help reduce active TB cases.
As a public health leader, your goal is to offer the people you serve in your community advanced diagnostic testing and treatment for TB, but your options are restricted by budget. With Oxford Immunotec’s insurance billing capabilities, many public health departments across the country are benefitting from access to the T-SPOT.TB test, within their existing budgets.
By accurately identifying TB infections through the use of the T-SPOT.TB test, public health can target intervention appropriately and move a step closer to eliminating TB.
¹WHO. The END TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. http://www.who.int/tb/post2015_TBstrategy.pdf?ua=1. Published 2013. Accessed August 31, 2015.
²CDC | TB | Testing & Diagnosis | Who Should be Tested. http://www.cdc.gov/tb/topic/testing/whobetested.htm. Accessed June 22, 2016.
3Oxford Immunotec Ltd. T-SPOT.TB Package Insert PI-TB-US-V5. March 2015